Late Breaking Abstract - Compare outcomes between COPD patients treated with Tiotropium/Olodaterol (TIO/OLO) and other fixed-dose LAMA/LABAs Source: Virtual Congress 2020 – COPD and the impact of comorbidities Year: 2020
Late Breaking Abstract - Compare outcomes between COPD patients treated with tiotropium/olodaterol (TIO/OLO) and umeclidium/vilanterol (UMEC/VI) Source: Virtual Congress 2020 – Burden and predictive factors for chronic lung diseases and comorbidity Year: 2020
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
Late Breaking Abstract - ND-L02-s0201 treatment leads to efficacy in preclinical IPF models Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017
Late Breaking Abstract - Masitinib in severe asthma: Results from a randomized, phase 3 trial Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020
Late Breaking Abstract - Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021
Late Breaking Abstract - Prolonged azithromycin maintenance treatment in patients with COPD, a follow-up of the COLUMBUS trial Source: International Congress 2019 – Blood eosinophils and more in airway diseases Year: 2019
Late Breaking Abstract - Long-term safety and efficacy of benralizumab in severe, uncontrolled asthma: first results of BORA, a randomized, Phase III extension study Source: International Congress 2018 – Notable Studies in Asthma Year: 2018
Late Breaking Abstract - Comparison of clinical characteristics between severe adult asthmatics in Brazil(ProAR) and Europe(U-BIOPRED). Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017
Late Breaking Abstract - The DIAMORFOSIS (DIAgnosis and Management Of lung canceR and FibrOSIS) survey. Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019
Late Breaking Abstract - Phase 1, first-in-human study of OATD-01, a dual chitinase inhibitor for the treatment of respiratory diseases Source: International Congress 2018 – What is new in idiopathic interstitial pneumonias? Year: 2018
Late Breaking Abstract - Effectiveness and safety of mepolizumab in real-world clinical practice: the REALITI-A study Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Late Breaking Abstract - Evaluation of the JNK inhibitor, CC-90001, in a phase 1b pulmonary fibrosis trial. Source: International Congress 2017 – Interstitial lung diseases (ILDs): novel pathogenetic pathways Year: 2017
Late Breaking Abstract - Efficacy of DPP1 inhibition with brensocatib in subgroups of patients with bronchiectasis- the WILLOW study Source: Virtual Congress 2020 – ALERT: Infection in adults and children Year: 2020
Late Breaking Abstract - Analysis of the InforMing the PAthway of COPD Treatment (IMPACT) study in the subgroup of patients taking triple therapy at screening Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018
Late Breaking Abstract - Efficacy and safety of macitentan in portopulmonary hypertension: the PORTICO trial Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018
Late Breaking Abstract - RPL554, a first-in-class dual PDE3/4 inhibitor, causes significant bronchodilation and symptom relief; a Phase 2b COPD study Source: International Congress 2018 – Novel drug targets for asthma and COPD Year: 2018
Late Breaking Abstract: Novel detection of exacerbations of COPD with patient reported outcome (EXACT-PRO) and Blackberry (BB) Source: Annual Congress 2010 - Asthma and COPD: understanding through monitoring Year: 2010
Late Breaking Abstract - Influence of salbutamol use on symptomatic outcomes with maintenance bronchodilators: a pre-specified analysis of the EMAX trial Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019
Late Breaking Abstract - Immunomodulatory and clinical effects of RIPK1 inhibitor SAR443122 in patients with severe COVID-19 Source: Virtual Congress 2021 – Back to infection basics Year: 2021